DOCSLIB.ORG

Dissertationes Medicinae Universitatis Tartuensis 106 Dissertationes Medicinae Universitatis Tartuensis 106

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dissertationes Medicinae Universitatis Tartuensis 106 Dissertationes Medicinae Universitatis Tartuensis 106 DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS 106 DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS 106 EPIDEMIOLOGY OF ADULT EPILEPSY IN TARTU, ESTONIA Incidence, prevalence and medical treatment ANDRE ÕUN TARTU UNIVERSITY PRESS Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia Dissertation is accepted for the commencement of the degree of Doctor of Medical Sciences on March 22, 2005 by the Council of the Faculty of Medicine, University of Tartu, Estonia Opponent: Dr. Tapani Keränen, University of Tampere, Finland Commencement: May 4, 2005 Publication of this dissertation is granted by the Faculty of Medicine, University of Tartu ISSN 1024–395X ISBN 9949–11–034–3 (trükis) ISBN 9949–11–035–1 (PDF)) Autoriõigus Andre Õun, 2005 Tartu Ülikooli Kirjastus www.tyk.ee Tellimus nr. 142 CONTENTS LIST OF ORIGINAL PUBLICATIONS......................................................... 8 ABBREVIATIONS......................................................................................... 9 I. INTRODUCTION ...................................................................................... 10 II. REVIEW OF THE LITERATURE ............................................................ 12 1. General aspects and methodology ......................................................... 12 1.1. Diagnostic accuracy ....................................................................... 12 1.2. Criteria, clinical characteristics and classifications........................ 13 1.2.1. Criteria for the activeness of epilepsy ................................. 14 1.2.2. Clinical characteristics and classifications .......................... 14 1.3. Case ascertainment......................................................................... 16 1.3.1. Reviews of the medical records........................................... 16 1.3.2. Door-to-door studies............................................................ 19 2. Incidence of epilepsy............................................................................. 20 2.1. General aspects of incidence.......................................................... 20 2.2. Age-specific incidence................................................................... 22 2.3. Seizure types .................................................................................. 23 2.4. Risk factors .................................................................................... 24 3. Prevalence of active epilepsy................................................................ 25 3.1. General aspects of prevalence ........................................................ 25 3.2. Age-specific prevalence ................................................................. 26 3.3. Clinical characteristics ................................................................... 27 3.4. Prevalence in Central and Eastern Europe ..................................... 27 4. Treatment of epilepsy............................................................................ 28 4.1. General aspects of antiepileptic treatment..................................... 28 4.2. Population-based reviews of antiepileptic treatment ..................... 29 III. AIMS OF THE STUDY ............................................................................ 33 IV. PATIENTS AND METHODS .................................................................. 34 1. Study area and population ..................................................................... 34 2. Definitions ............................................................................................. 35 2.1. Epileptic seizure and epilepsy........................................................ 35 2.2. Classification of seizure types........................................................ 35 2.3. Risk factors .................................................................................... 36 2.4. Classification of epilepsies and epileptic syndromes..................... 37 3. Case ascertainment and data collection................................................. 37 3.1. Case ascertainment......................................................................... 37 3.2. Collection of general data .............................................................. 38 3.3. Collection of treatment data........................................................... 38 5 4. Statistical analysis................................................................................. 39 5. Ethics..................................................................................................... 39 V. RESULTS................................................................................................... 40 1. Incidence of adult epilepsy ................................................................... 40 1.1. Provisional study group ................................................................. 40 1.2. Incidence rates ............................................................................... 41 1.3. Seizure types.................................................................................. 41 1.4. Risk factors .................................................................................... 41 1.5. Syndromic diagnoses ..................................................................... 45 2. Prevalence of adult epilepsy ................................................................. 46 2.1. Provisional study group ................................................................. 46 2.2. Prevalence rates ............................................................................. 46 2.3. Seizure types.................................................................................. 48 2.4. Risk factors.................................................................................... 48 2.5. Syndromic diagnoses..................................................................... 49 3. Medical treatment ................................................................................. 49 3.1. General characteristics................................................................... 49 3.2. Medication strategies..................................................................... 50 3.3. Utilization of particular drugs........................................................ 50 3.4. Doses of drugs............................................................................... 52 3.5. Speciality of permanent doctors .................................................... 54 VI. DISCUSSION ........................................................................................... 55 1. General aspects and methodology........................................................ 55 2. Incidence of adult epilepsy................................................................... 56 2.1. Incidence rates............................................................................... 56 2.2. Age-specific incidence .................................................................. 56 2.3. Seizure types.................................................................................. 57 2.4. Risk factors.................................................................................... 57 2.5. Syndromic diagnoses..................................................................... 58 3. Prevalence of adult epilepsy................................................................. 59 3.1. Prevalence rates............................................................................. 59 3.2. Age-specific prevalence................................................................ 59 3.3. Seizure types ................................................................................. 60 3.4. Risk factors ................................................................................... 60 3.5. Syndromic diagnoses .................................................................... 61 4. Medical treatment................................................................................. 61 4.1. General characteristics .................................................................. 61 4.2. Medication strategies .................................................................... 62 4.3. Utilization of particular drugs....................................................... 62 4.4. Doses of drugs............................................................................... 63 4.5. Speciality of permanent doctors.................................................... 64 6 VII. CONCLUSIONS...................................................................................... 65 VIII. REFERENCES ....................................................................................... 66 SUMMARY IN ESTONIAN ......................................................................... 74 ACKNOWLEDGEMENTS............................................................................. 79 PUBLICATIONS ............................................................................................ 81 7 LIST OF ORIGINAL PUBLICATIONS I Õun A, Haldre S, Mägi M. Incidence of adult epilepsy in Estonia. Acta Neurologica Scandinavica 2003; 108: 245–251. II Õun A, Haldre S, Mägi M. Prevalence of adult epilepsy in Estonia. Epi- lepsy Research 2003; 52: 233–242. III Õun A, Haldre S, Mägi M. Use of antiepileptic drugs in Estonia: an epidemiologic study of adult epilepsy. European Journal of Neurology (submitted). IV Õun A, Haldre S. Aktiivne epilepsia Tartu täiskasvanutel: epidemioloogi- lised näitajad ja ravi (in Estonian). Eesti Arst
Load more

Recommended publications
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Excipient: 0.4 Mg Lactose Monohydrate/Film-Coated Tablet
    1. NAME OF THE MEDICINAL PRODUCT [[Topiramate]25 mg film-coated tablets [Topiramate] 50 mg film-coated tablets [Topiramate] 100 mg film-coated tablets [Topiramate] 200 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 25 mg film-coated tablets Each film-coated tablet contains 25 mg of topiramate. Excipient: 0.4 mg lactose monohydrate/film-coated tablet. 50 mg film-coated tablets Each film-coated tablet contains 50 mg of topiramate. Excipient: 0.4 mg lactose monohydrate/film-coated tablet. 100 mg film-coated tablets Each film-coated tablet contains 100 mg of topiramate. Excipient: 0,05 mg sunset yellow (E110)/film-coated tablet. 200 mg film-coated tablets Each film-coated tablet contains 200 mg of topiramate. Excipient: 3.2 mg lactose monohydrate/film-coated tablet. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. [Topiramate] 25 mg are available as white, round, biconvex film-coated tablets. [Topiramate] 50 mg are available as yellow, round, biconvex film-coated tablets. [Topiramate] 100 mg are available as orange, oblong, biconvex film-coated tablets. [Topiramate] 200 mg are available as pink, oblong, biconvex film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Monotherapy in adults, adolescents and children over 6 years of age with partial seizures with or without secondary generalised seizures and primary generalised tonic-clonic seizures. Adjunctive therapy in children aged 2 years and above, adolescents and adults with partial onset seizures with or without secondary generalization or primary generaliszed tonic-clonic seizures and for the treatment of seizures associated with Lennox-Gastaut syndrome.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Classification and Analysis of a Large Collection of in Vivo Bioassay Descriptions
    RESEARCH ARTICLE Classification and analysis of a large collection of in vivo bioassay descriptions Magdalena Zwierzyna1,2, John P. Overington1,2¤* 1 BenevolentAI, London, United Kingdom, 2 Institute of Cardiovascular Science, University College London, London, United Kingdom ¤ Current address: Medicines Discovery Catapult, Mereside, Alderley Park, Alderley Edge, Cheshire, United Kingdom * [email protected] a1111111111 a1111111111 a1111111111 a1111111111 Abstract a1111111111 Testing potential drug treatments in animal disease models is a decisive step of all preclini- cal drug discovery programs. Yet, despite the importance of such experiments for transla- tional medicine, there have been relatively few efforts to comprehensively and consistently analyze the data produced by in vivo bioassays. This is partly due to their complexity and OPEN ACCESS lack of accepted reporting standardsÐpublicly available animal screening data are only Citation: Zwierzyna M, Overington JP (2017) accessible in unstructured free-text format, which hinders computational analysis. In this Classification and analysis of a large collection of in study, we use text mining to extract information from the descriptions of over 100,000 drug vivo bioassay descriptions. PLoS Comput Biol 13(7): e1005641. https://doi.org/10.1371/journal. screening-related assays in rats and mice. We retrieve our dataset from ChEMBLÐan pcbi.1005641 open-source literature-based database focused on preclinical drug discovery. We show that Editor: Nir London, Weizmann Institute of Science, in vivo assay descriptions can be effectively mined for relevant information, including experi- ISRAEL mental factors that might influence the outcome and reproducibility of animal research: Received: February 27, 2017 genetic strains, experimental treatments, and phenotypic readouts used in the experiments.
    [Show full text]
  • Original Article No Signal of Interactions Between Influenza Vaccines and Drugs Used for Chronic Diseases
    Original Article No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase Carla Carnovale1*, Emanuel Raschi2*, Luca Leonardi2, Ugo Moretti3, Fabrizio De Ponti2, Marta Gentili1, Marco Pozzi4, Emilio Clementi4,5, Elisabetta Poluzzi2§ and Sonia Radice1§ 1 Unit of Clinical Pharmacology Department of Biomedical and Clinical Sciences L. Sacco, “Luigi Sacco” University Hospital, Università di Milano, 20157 Milan, Italy. 2 Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, BO, Italy. 3 Dept. of Diagnostics and Public Health, Section of Pharmacology, University of Verona, Verona, Italy. 4 Scientific Institute, IRCCS E. Medea, Bosisio Parini LC, Italy. 5 Clinical Pharmacology Unit, Department Biomedical and Clinical Sciences, CNR Institute of Neuroscience, L. Sacco University Hospital, Università di Milano, Milan, Italy. *Carla Carnovale and Emanuel Raschi contributed equally to this work §Sonia Radice and Elisabetta Poluzzi jointly directed this work. *Corresponding author: Emilio Clementi, Department of Biomedical and Clinical Sciences, Università di Milano Via GB Grassi, 74 - 20157 Milan, Tel: +39.02.50319643. Fax: +39.02.50319682 e-mail: [email protected] 1 ABSTRACT Background: An increasing number of reports indicates that vaccines against influenza may interact with specific drugs via drug metabolism. To date, actual impact of vaccine-drug interactions observed in the real world clinical practice has not been investigated. Research design and methods: From VAERS and VigiBase, we collected Adverse Event Following Immunization (AEFI) reports for individuals receiving vaccines against influenza recorded as suspect and selected cases where predictable toxicity was recorded with oral anticoagulants, antiepileptics and statins (i.e., hemorrhages, overdosage and rhabdomyolysis, respectively).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,261,537 B1 Klaveness Et Al
    USOO626.1537B1 (12) United States Patent (10) Patent No.: US 6,261,537 B1 Klaveness et al. (45) Date of Patent: *Jul.17, 2001 (54) DIAGNOSTIC/THERAPEUTICAGENTS 5,632,983 5/1997 Tait et al.. HAVING MICROBUBBLES COUPLED TO 5,643,553 * 7/1997 Schneider et al. .................. 424/9.52 ONE OR MORE VECTORS 5,650,156 7/1997 Grinstaff et al. ..................... 424/400 5,656.211 * 8/1997 Unger et al. .......................... 264/4.1 5,665,383 9/1997 Grinstaff et al. (75) Inventors: Jo Klaveness; Pál Rongved; Anders 5,690,907 11/1997 Lanza et al. .......................... 424/9.5 Høgset; Helge Tolleshaug, Anne 5,716,594 2/1998 Elmaleh et al. Naevestad; Halldis Hellebust; Lars 5,733,572 3/1998 Unger et al.. Hoff, Alan Cuthbertson; Dagfinn 5,780,010 7/1998 Lanza et al. Levhaug, Magne Solbakken, all of 5,846,517 12/1998 Unger. Oslo (NO) 5,849,727 12/1998 Porter et al.. 5,910,300 6/1999 Tournier et al. .................... 424/9.34 (73) Assignee: Nycomed Imaging AS, Oslo (NO) FOREIGN PATENT DOCUMENTS (*) Notice: This patent issued on a continued pros ecution application filed under 37 CFR 2 145 505 4/1994 (CA). 19 626 530 1/1998 (DE). 1.53(d), and is subject to the twenty year 0 727 225 8/1996 (EP). patent term provisions of 35 U.S.C. WO91/15244 10/1991 (WO). 154(a)(2). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). Subject to any disclaimer, the term of this WO 94/28873 12/1994 (WO).
    [Show full text]